Search companies on Owler
Advanced Search
Latest news
Newsfeed
My followed companies
Followed Companies

Oncopeptides's Competitors, Revenue, Number of Employees, Funding and Acquisitions

Oncopeptides is a pharmaceutical company that develops therapies for hematological diseases.

Oncopeptides is headquartere... Read more

Marty J Duvall's photo - CEO of Oncopeptides

CEO

Marty J Duvall

CEO Approval Rating

- -/100

Founded:

2000

Status:

Private

Est. Annual Revenue
Est. Employees
Sector

Update Industry
Headquarters

Weigh-in!

Help the Owler community know more

Growth Score - 1/1

Is 10 a good estimate for Oncopeptides's Employee count?

I don't know

Acquisitions

No recent acquisitions found related to Oncopeptides

Investments

No recent investments found related to Oncopeptides

Oncopeptides News

June 16, 2020Pharmabiz

Oncopeptides presents positive results from phase 2 HORIZON study of melflufen in combo with dexamethasone to treat RRMM at EHA meeting

Oncopeptides AB announces that the full top─line results from the pivotal phase 2 HORIZON study, eval... See more »
June 11, 2020MarketScreener

Oncopeptides Hosts a Virtual Symposium at the 25th European Hematology Association Congress on Challenges in Managing Patients with Myeloma

(marketscreener.com) STOCKHOLM, June 11, 2020 /PRNewswire/ -- Oncopeptides AB announces today that th... See more »
June 2, 2020Pharmabiz

Oncopeptides announces positive results from OCEAN study between melflufen & pomalidomide in patients with RRMM

Oncopeptides AB announces that patients in the OCEAN study stay on treatment longer than previously e... See more »
June 1, 2020FinanzNachrichten

New Analysis Confirms That Multiple Myeloma Patients in the OCEAN Study Stay on Treatment Longer Than Previously Estimated - Results Expected H1-2021

STOCKHOLM, June 1, 2020 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO) announces that patie... See more »
May 29, 2020BioSpace

Number of shares and votes in Oncopeptides - May 29, 2020

Oncopeptides AB announces that the number of shares and votes in Oncopeptides has changed as a result... See more »
May 27, 2020FinanzNachrichten

Oncopeptides Reinitiates Patient Enrollment to the Melflufen Clinical Program Following a Temporary Pause due to the COVID-19 Pandemic

STOCKHOLM, May 28, 2020 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO) announces that the c... See more »
May 26, 2020FinanzNachrichten

Bulletin From the Annual General Meeting in Oncopeptides AB (publ)

STOCKHOLM, May 26, 2020 /PRNewswire/ -- Oncopeptides AB (publ)'s (ONCO) Annual General Meeting 2020 w... See more »

Oncopeptides Press Releases

September 24, 2019centralcharts

Exercise of Options and Sale of Shares Under the Employee Stock Option Program 2012/2019

Exercise of Options and Sale of Shares Under the Employee Stock Option Program 2012/2019 PR Newswire ... See more »
September 11, 2019PR Newswire

Data From Oncopeptides Melflufen Clinical Development Program Presented at SOHO 2019 Annual Meeting

STOCKHOLM, Sept. 11, 2019 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today th... See more »
May 28, 2019PR Newswire

Oncopeptides to Present at the Jefferies Healthcare Conference in New York on June 7th at 11.30am EST

STOCKHOLM, May 28, 2019 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that... See more »
May 20, 2019PR Newswire

Oncopeptides to Apply for Accelerated Approval in the US

STOCKHOLM, May 20, 2019 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that... See more »
April 24, 2019PR Newswire

Oncopeptides Provides New Guidance on the Patient Recruitment in the OCEAN Study and a Clinical Program Update in a Webcast at 10:00 (CET)

STOCKHOLM, April 24, 2019 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today th... See more »
April 11, 2019PR Newswire

Updated Financial Calendar

STOCKHOLM, April 11, 2019 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO) today announced th... See more »
February 28, 2019PR Newswire

Data From Oncopeptides Clinical Trials HORIZON and ANCHOR Evaluating Melflufen in RRMM Selected for Presentation at the AACR Annual Meeting

STOCKHOLM, Feb. 28, 2019 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO) today announced tha... See more »

Headquarters

Luntmakargatan 46 Floor 7

Stockholm, Stockholms länSE-111 37

46-8-615-20-40

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Oncopeptides is a pharmaceutical company that develops therapies for hematological diseases. Oncopeptides was founded in 2000. Oncopeptides' headquarters is located in Stockholm, Stockholms län, SE SE-111 37. Oncopeptides has an estimated 10 employees...

Website

oncopeptides.se

Frequently Asked Questions about Oncopeptides

  1. When was Oncopeptides founded?

    Oncopeptides was founded in 2000

  2. Who is Oncopeptides's CEO?

    Oncopeptides's CEO is Marty J Duvall

  3. How much revenue does Oncopeptides generate?

    Oncopeptides generates $10M in revenue

  1. How much funding does Oncopeptides have?

    Oncopeptides has historically raised $0 in funding

  2. Where is Oncopeptides's headquarters?

    Oncopeptides's headquarters is in Stockholm Stockholms län, SE

  3. How many employees does Oncopeptides have?

    Oncopeptides has 10 employees
Stay up-to-date with the latest news on Oncopeptides